MA50352A - Anticorps multispécifiques - Google Patents

Anticorps multispécifiques

Info

Publication number
MA50352A
MA50352A MA050352A MA50352A MA50352A MA 50352 A MA50352 A MA 50352A MA 050352 A MA050352 A MA 050352A MA 50352 A MA50352 A MA 50352A MA 50352 A MA50352 A MA 50352A
Authority
MA
Morocco
Prior art keywords
multispecific antibodies
multispecific
antibodies
Prior art date
Application number
MA050352A
Other languages
English (en)
Inventor
Matthias Brock
Tea Gunde
Christian Hess
Sebastian Meyer
Alexandre Simonin
David Urech
Stefan Warmuth
Original Assignee
Numab Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP17195779.8A external-priority patent/EP3470426A1/fr
Application filed by Numab Therapeutics AG filed Critical Numab Therapeutics AG
Publication of MA50352A publication Critical patent/MA50352A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA050352A 2017-10-10 2018-10-09 Anticorps multispécifiques MA50352A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17195779.8A EP3470426A1 (fr) 2017-10-10 2017-10-10 Anticorps multi-spécifique
EP18150465 2018-01-05
EP18167093 2018-04-12
EP18180814 2018-06-29

Publications (1)

Publication Number Publication Date
MA50352A true MA50352A (fr) 2020-08-19

Family

ID=63799025

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050352A MA50352A (fr) 2017-10-10 2018-10-09 Anticorps multispécifiques

Country Status (16)

Country Link
US (1) US12202911B2 (fr)
EP (1) EP3694873A1 (fr)
JP (1) JP7442443B2 (fr)
CN (1) CN111194323B (fr)
AU (1) AU2018348429B2 (fr)
BR (1) BR112020006999A2 (fr)
CA (1) CA3075969A1 (fr)
CL (2) CL2020000937A1 (fr)
CO (1) CO2020003882A2 (fr)
IL (1) IL273576A (fr)
MA (1) MA50352A (fr)
MX (1) MX2020003562A (fr)
PE (1) PE20200849A1 (fr)
SG (1) SG11202002982YA (fr)
WO (1) WO2019072868A1 (fr)
ZA (1) ZA202001294B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019017628A2 (pt) 2017-02-24 2020-07-07 Macrogenics, Inc. molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
ES3015094T3 (en) * 2017-06-05 2025-04-29 Numab Therapeutics AG Anti-hsa antibodies
CA3075337A1 (fr) * 2017-10-10 2019-04-18 Numab Therapeutics AG Anticorps ciblant le cd137 et leurs methodes d'utilisation
KR20200080304A (ko) * 2017-11-13 2020-07-06 크레센도 바이오로직스 리미티드 Cd137에 결합하는 단일 도메인 항체
TWI839395B (zh) * 2018-10-09 2024-04-21 瑞士商Ｎｕｍａｂ治療公司 靶向cd137的抗體及其使用方法
WO2021013142A1 (fr) * 2019-07-22 2021-01-28 江苏恒瑞医药股份有限公司 Anticorps anti-4-1bb, fragment de liaison à l'antigène de celui-ci et anticorps bispécifique
EP4041772A4 (fr) 2019-10-11 2024-04-24 Nanjing Leads Biolabs Co., Ltd. Anticorps se liant au 4-1bb et leurs utilisations
EP3816185A1 (fr) * 2019-11-04 2021-05-05 Numab Therapeutics AG Anticorps multi-spécifique contra pd-l1 et antigène associé à une tumeur
WO2021140130A1 (fr) * 2020-01-09 2021-07-15 F. Hoffmann-La Roche Ag Nouvelles molécules de liaison à l'antigène contenant un trimère de 4-1bbl
CA3180665A1 (fr) 2020-05-19 2021-11-25 Boehringer Ingelheim International Gmbh Molecules de liaison pour le traitement du cancer
BR112022024161A2 (pt) * 2020-05-29 2023-02-07 Numab Therapeutics AG Anticorpo multiespecífico, sequência de ácido nucleico, vetor, célula hospedeira, método para produzir o anticorpo multiespecífico e composição farmacêutica
CN114195900B (zh) * 2020-09-17 2024-02-23 普米斯生物技术(珠海)有限公司 一种抗4-1bb/pd-l1双特异性抗体及其用途
EP3988568A1 (fr) 2020-10-21 2022-04-27 Numab Therapeutics AG Traitement combiné
WO2022136693A1 (fr) 2020-12-23 2022-06-30 Numab Therapeutics AG Domaines variables d'anticorps et anticorps ayant une immunogénicité réduite
IL310292A (en) 2021-07-22 2024-03-01 Univ Dundee Medicinal myotains
EP4273162A1 (fr) 2022-05-06 2023-11-08 Numab Therapeutics AG Domaines variables d'anticorps et anticorps présentant une immunogénicité réduite
IL316376A (en) 2022-05-06 2024-12-01 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
WO2024240690A2 (fr) 2023-05-19 2024-11-28 Numab Therapeutics AG Domaines variables d'anticorps et anticorps présentant une immunogénicité réduite
WO2025133389A1 (fr) 2023-12-22 2025-06-26 Numab Therapeutics AG Domaines de liaison à un anticorps ayant une spécificité pour lilrb2

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
ATE249840T1 (de) 1991-12-13 2003-10-15 Xoma Corp Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
JP2003518075A (ja) 1999-12-24 2003-06-03 ジェネンテック・インコーポレーテッド 生理活性化合物の消失半減期延長のための方法及び組成物
CA2440582A1 (fr) 2001-03-09 2002-10-03 Dyax Corp. Groupes de liaison d'albumine serique
US20030157561A1 (en) * 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
ATE395413T1 (de) 2001-12-03 2008-05-15 Amgen Fremont Inc Antikörperkategorisierung auf der grundlage von bindungseigenschaften
EP1576172A2 (fr) 2002-06-21 2005-09-21 Dyax Corporation Ligands propres a un cible et associes a une proteine serique et procede d'identification correspondant
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
AU2003244817B2 (en) 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
PL375144A1 (en) 2002-07-30 2005-11-28 Bristol-Myers Squibb Company Humanized antibodies against human 4-1bb
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CA2502413A1 (fr) 2002-11-01 2004-05-21 The Regents Of The University Of Colorado, A Body Corporate Analyse quantitative d'isoformes de proteines utilisant la spectrometrie de masse a temps de vol par desorption/ionisation laser assistee par matrice
AU2005250216B2 (en) 2004-06-01 2009-12-10 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
EP1841796A2 (fr) 2004-12-02 2007-10-10 Domantis Limited Anticorps bispecifiques de domaine visant l'albumine serique et glp-1 ou pyy
KR101607288B1 (ko) 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
ES2975748T3 (es) 2007-06-26 2024-07-12 F Star Therapeutics Ltd Presentación de agentes de unión
CA2700714C (fr) 2007-09-26 2018-09-11 Ucb Pharma S.A. Fusions d'anticorps a double specificite
PT2334705T (pt) 2008-09-26 2017-03-22 Ucb Biopharma Sprl Produtos biológicos
TWI729512B (zh) 2008-12-09 2021-06-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
SG177601A1 (en) 2009-07-16 2012-02-28 Glaxo Group Ltd Improved anti-serum albumin binding single variable domains
CN104961829B (zh) 2009-11-24 2018-08-21 米迪缪尼有限公司 针对b7-h1的靶向结合剂
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
SG10201912092VA (en) 2010-09-09 2020-02-27 Pfizer 4-1bb binding molecules
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
MA41044A (fr) * 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
HRP20211273T1 (hr) * 2014-11-26 2021-11-12 Xencor, Inc. Heterodimerna protutijela koja vežu cd3 i cd20
AU2016219772A1 (en) * 2015-02-22 2017-09-21 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD137
WO2016149201A2 (fr) 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
KR20180012860A (ko) 2015-06-15 2018-02-06 누맙 이노베이션 아게 이종 이량체 다중 특이적 항체 포맷
WO2017102835A1 (fr) * 2015-12-14 2017-06-22 Complix Nv Molécule de liaison comprenant un polypeptide-alphacorps et un anticorps
BR112018013677A2 (pt) * 2016-01-11 2019-01-22 Inhibrx Inc proteínas de fusão de ligação de 41bb multivalentes e multiespecíficas
CA3075337A1 (fr) * 2017-10-10 2019-04-18 Numab Therapeutics AG Anticorps ciblant le cd137 et leurs methodes d'utilisation

Also Published As

Publication number Publication date
ZA202001294B (en) 2024-08-28
AU2018348429B2 (en) 2025-08-28
MX2020003562A (es) 2020-10-01
CO2020003882A2 (es) 2020-05-29
CA3075969A1 (fr) 2019-04-18
CN111194323A (zh) 2020-05-22
AU2018348429A1 (en) 2020-03-12
SG11202002982YA (en) 2020-04-29
JP7442443B2 (ja) 2024-03-04
CL2020000937A1 (es) 2020-09-25
CL2021000028A1 (es) 2021-05-28
KR20200063155A (ko) 2020-06-04
US12202911B2 (en) 2025-01-21
JP2021501744A (ja) 2021-01-21
IL273576A (en) 2020-05-31
BR112020006999A2 (pt) 2020-10-06
PE20200849A1 (es) 2020-08-20
US20230192897A1 (en) 2023-06-22
CN111194323B (zh) 2024-07-09
WO2019072868A1 (fr) 2019-04-18
EP3694873A1 (fr) 2020-08-19

Similar Documents

Publication Publication Date Title
MA50352A (fr) Anticorps multispécifiques
IL272227A (en) Anti-tigit antibodies
MA47694A (fr) Anticorps anti-tigit
MA49034A (fr) Anticorps anti-lag3
EP3423089A4 (fr) Anticorps anti-tigit
MA47268A (fr) Anticorps anti-gpc3
EP3334757A4 (fr) Anticorps anti-tigit
EP3297671A4 (fr) Anticorps anti-ror1
DK3625259T3 (da) Anti-sirpalpha-antistoffer
FR25C1022I1 (fr) Anticorps anti-pd-1
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
EP3661558A4 (fr) Anticorps anti-il1rap
EP3387442A4 (fr) Anticorps anti-cd73 humanisés
MA53297A (fr) Anticorps anti-icos
MA46057A (fr) Anticorps anti-ctla4
EP3334824A4 (fr) Anticorps anti-pd-1
MA47472A (fr) Anticorps
EP3691447A4 (fr) Anticorps anti-transthyrétine
DK3606961T3 (da) Garp-tgf-beta-antistoffer
EP3526247A4 (fr) Anticorps anti-il1-rap
EP3399992A4 (fr) Anticorps autoréticulants
EP3383915A4 (fr) Anticorps anti-pd-1
EP3617231A4 (fr) Anticorps anti-gpc-1
EP3349794A4 (fr) Anticorps anti-cd115
MA51134A (fr) Anticorps anti-alpha-synucléine